A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: A nested case-control study

Annals of the Rheumatic Diseases

Volumn 66, Issue 12, 2007, Pages 1627-1632

  Lofstrom B ^a,b   Backlin, C ^c   Sundstrom C ^c   Ekbom, A ^d   Lundberg, I E ^d  

^a Malar Hospital   (Sweden)

^b Malar Hospital   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; GLUCOCORTICOID; INTERFERON REGULATORY FACTOR 4; LOMUSTINE; METHOTREXATE; PREDNIMUSTINE; PREDNISOLONE; PROTEIN BCL 6; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; GERMINAL CENTER; HEMATOLOGIC DISEASE; HOSPITAL DISCHARGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MEDICAL RECORD; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTIGENS, VIRAL; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RISK ASSESSMENT; SURVIVAL ANALYSIS; SWEDEN;

EID: 35548969613     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.067108     Document Type: Article

References (33)

1. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978;89:888-92.
2. Isomäki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukaemia and myeloma in patients with rheumatoid arthritis. J Chron Dis 1978;31:691-6.
3. Pettersson T, Pukkala E, Teppo L, Friman C. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 1992;51:437-9.
4. Abu-Shakra M, Gladman DD, Urowitz MB. Malignancy in systemic lupus erythematosus. Arthritis Rheum 1996;39:1050-4.
5. Sultan SM, Ioannou Y, Isenberg D. Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology 2000;39:1147-52.
6. Nived O, Bengtsson A, Jonsen A, Sturfelt G, Olsson H. Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden. Lupus 2001;10:500-4.
7. Cibere J, Sibley J, Haga M. Systemic lupus erythematosus and the risk of malignancy. Lupus 2001;10:388-91.
8. Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, et al. An international cohort study or cancer in systemic lupus erythematosus. Arthritis Rheum 2005;52:1481-90.
9. Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:761-8.
10. Bjornadal L, Lofstrom B, Yin L, Lundberg I, Ekbom A. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 2000;31:66-71.
11. Baecklund E, Sundstrom C, Ekbom A, Catrina AI, Biberfeld P, Feltelius N, et al. Lymphoma subtypes in patients with rheumatoid arthritis. Increased proportion of diffuse large B cell lymphoma. Arthritis Rheum 2003;48:1543-50.
12. Bernatsky S, Ramsey-Goldman R, Rajan R, Boivin JF, Joseph L, Lachance S, et al. Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis 2005;64:1507-9.
13. World Health Organization. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Geneva: IARC Press, 2001.
14. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
15. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson L. Lymphoma and other malignancies in primary Sjögren's syndrome. A cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2005;64:1507-9.
16. Bernatsky S, Clarke A, Ramsey-Goldman R. Malignancy and systemic lupus erythematosus. Curr Rheumatol Rep 2002;4:351-8.
17. Alizadeh AA, Eisen MB, Davis RE, Chi Ma, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
18. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 2002;346:1937-47.
19. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82.
20. Berglund M, Thunberg U, Amini RM, Book M, Roos G, Erlanson M, et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and impact on prognosis. Mod Pathol 2005;18:1113-20.
21. Hochberg MC. Updating the American college of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
22. Carbone PP, Kaplan HS, Musskoff H, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1.
23. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-94.
24. Barrans SL, Carter I, Owen RG, Davies FE, Patmore RD, Haynes AP, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002;99:1136-43.
25. Colomo L, Lopez-Guillermo A, Perales M, Rives S, Martinez A, Bosch F, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003;101:78-84.
26. Linderoth J, Jerkeman M, Cavallin-Stahl E, Kvaloy S, Torlakovic E. Immunohistochemical expression of CD23 and CD40 may identify prognostically favourable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. Clin Cancer Res 2003;9:722-8.
27. Chang C-C, McClintock S, Cleveland RP, Trzpuc T, Vesole DH, Logan B, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004;28:464-70.
28. Baecklund E, Ekbom A, Sparén P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317:180-1.
29. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Chronic inflammation, not its treatment, increases lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
30. Verdolini R, Bugatti L, Gianciacomi M, Nicolini M, Filosa G, Cerio R. Systemic lupus erythematosus induced by Epstein-Barr virus. Br J Dermatol 2002;146:877-81.
31. Stahl-Hallengren C, Jonsen A, Nived O, Sturfelt G. Incidence studies of systemic lupus erythematosus in southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol 2000;27:685-91.
32. Nilsson AC, Spetz CL, Carsjö K, Nightingale R, Smedby A. Slutenvårdsregistrets tillförlitlighet. Diagnosuppgifterna bättre än sitt rykte. Läkartidningen 1994;91:598- 605.
33. Ramos-Casals M, Brito-Zeron P, Font J. The overlap of Sjögren's syndrome with other systemic autoimmune diseases. Semin Arthritis Rheum 2007;36:246-55.